Abstract
Kinesin family protein 2A (KIF2A), an M-type nonmotile microtubule depolymerase, has attracted attention for its role in carcinogenesis and poor prognoses in various human cancers. In this study, we aimed to evaluate the expression of KIF2A and its robustness and potential to predict clinical outcomes in gastric cancer (GC) patients. The messenger RNA (mRNA) expression of KIF2A was determined in 24 pairs of cancerous and adjacent nontumor tissues by real-time polymerase chain reaction. Immunohistochemistry of KIF2A was performed on a tissue microarray composed of 461 GC and 65 matched adjacent nontumor tissues removed during surgeries and 18 chronic gastritis, 15 intestinal metaplasia, and 37 low-grade and 62 high-grade intraepithelial neoplasias acquired through gastric endoscopic biopsies. Univariate and multivariate Cox regression models were used to perform survival analyses. The high KIF2A expression was significantly correlated to histological type, TNM stage, and lymph node metastasis. A negative correlation was found between KIF2A expression and the 5-year survival rate of GC patients. In addition, multivariate analysis indicated that KIF2A is an independent prognostic factor in GC. This study demonstrated the high KIF2A expression might serve as an independent marker for poor prognoses in GC patients.
Highlights
Gastric cancer (GC) is one of the most prevalent and aggressive cancers worldwide with 952,000 new cases diagnosed annually [1, 2]
We explored Kinesin family protein 2A (KIF2A) expression by performing IHC analysis on Tissue microarrays (TMAs) comprising 461 GC and 65 matched tumor adjacent tissues from patients with GC
We examined KIF2A expression in 18 chronic gastritis, 15 intestinal metaplasia, and 37 lowgrade and 62 high-grade intraepithelial neoplasias
Summary
Gastric cancer (GC) is one of the most prevalent and aggressive cancers worldwide with 952,000 new cases diagnosed annually [1, 2]. Notwithstanding rapid advances in treatments, including surgery, chemotherapy, and targeted therapy, the prognosis for GC patients is far from satisfying [4]. High rates of metastasis and recurrence are major obstacles to improving long-term survival after a curative resection [5, 6]; new molecular prognostic markers and therapeutic targets are needed to improve the clinical outcome for patients with this disease. Countless efforts have been made to pinpoint reliable GC prognostic biomarkers based on tumor biology [7], many issues, such as reproducibility and specificity, still need to be addressed and much work is needed to identify high-quality GC prognostic markers
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
